DUET Acquisition Corp Ordinary Shares - Class A DUET 深 沪
等待开盘 10-02 09:30:00 美东时间
11.3312
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 11.3312
- 总市值 4437.07万
- 52周最高 11.47
- 市盈率 静 446.11
- 换手率 0.00%
- 52周最低 10.82
- 委 比 0.00%
- 总股本 391.58万
- 历史最高 11.83
- 量 比 0
- 振 幅 0.00%
- 历史最低 9.78
- 每 手 1
- 风险率 0.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jazz Pharma's Xywav Shows Phase 4 Results Improving Sleep And Daytime Alertness In Narcolepsy, Hypersomnia Patients
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav® (calcium, magnesium, potassium, and sodium oxybates)
09-22 19:46
Travere Shares Are Trading Higher Wednesday: What's Going On?
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday...
09-11 03:52
Travere Therapeutics Announces FDA Drops Advisory Committee For FILSPARI sNDA In FSGS; PDUFA Target Date Set For January 13, 2026
Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for
09-10 19:03
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
08-29 00:40
Travere Therapeutics to submit SNDA for its kidney disorder treatment
Travere Therapeutics (NASDAQ:TVTX) completed its Type C meeting with the U.S. Food and Drug Administration and plans to submit a supplemental New Drug Application seeking traditional approval of FILSP...
02-11 20:51
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
Thirteen abstracts, including five late-breaking abstracts, underscore Jazz's ongoing commitment to advancing the understanding and treatment of serious sleep disorders Oral presentation of ...
2024-05-30 19:30
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
2023-12-05 22:05
Terns Achieves Primary Endpoint And All Secondary Endpoints In Phase 2a DUET Trial Of THR-β Agonist TERN-501 In NASH
TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction
2023-08-09 05:42
DUET 收购公司（纳斯达克股票代码：DUET）3月份空头利率上涨14.3％
DUET Acquisition Corp. (NASDAQ:DUET – Get Rating) saw a significant growth in s...
2023-04-03 05:32
